- Home
- HOLO vs LIXT Comparison
HOLO vs LIXT Comparison
Compare HOLO & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOLO | LIXT |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | China | United States |
| Employees | 64 | 4 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 25.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HOLO | LIXT |
|---|---|---|
| Price | $1.92 | $3.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 320.5K | 37.9K |
| Earning Date | 08-10-2023 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.64 |
| 52 Week High | $12.75 | $6.09 |
Technical Indicators
Market Signals| Indicator | HOLO | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 36.70 | 52.14 |
| Support Level | N/A | $2.97 |
| Resistance Level | $2.30 | $3.30 |
| Average True Range (ATR) | 0.13 | 0.28 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 11.11 | 66.25 |
Price Performance
Historical ComparisonAbout HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.